- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00593983
Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials (the ACT2 Project)
Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
According to a 2001 report by the U.S. Census Bureau, African Americans and Latinos make up 65% of all AIDS cases reported in the United States, yet they make up only 25% of the population in the United States. In addition, the number of women living with HIV/AIDS, many of whom are minorities, is rapidly increasing. ACTs are research studies designed to evaluate new therapies to fight HIV infection and prevent and treat opportunistic infections and cancers associated with AIDS. Preliminary research suggests that intensive intervention efforts are needed to improve rates of screening and to enroll more racial/ethnic minorities and women in ACTs. The purpose of this study is to identify effective intervention strategies to increase the low number of HIV infected racial/ethnic minorities and women who are screened for and enrolled into ACTs.
Each participant will be enrolled in the study for 12 months. Participants will be randomly assigned to either the intervention or control arm. Initial "seed" participants in the intervention arm will complete a peer-driven intervention consisting of four structured intervention sessions lasting 6 hours in total (occurring every week for 4 weeks), three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening. Participants in the control arm will complete a time-matched health education intervention lasting 6 hours. Participants in the control arm will also receive the community standard of care and be referred to their local ACT unit. Peer participants will be recruited by either a seed or through general recruitment; those recruited by an initial seed will participate in the same arm as the see d who recruited them. Study visits will occur throughout the study. Participants in the intervention arm will complete an interview at Week 30. At Weeks 8, 16 and 52, all participants will complete social impact assessments. At Weeks 16 and 52, all participants will complete follow-up visits.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria for Initial Seeds:
- HIV infected
- Seen at the Betances Health Center or AIDS Service Center at least once in the last 6 months prior to study entry
- Of African-American or Latino descent
- Willing to recruit HIV infected peers
- Able to conduct research activities (e.g., speaking and writing when necessary) in English
Inclusion Criteria for Peers:
- Documented recruitment for study participation
- HIV infected
- Willing to recruit HIV infected peers
- Able to conduct research activities (e.g., speaking and writing when necessary) in English
Exclusion Criteria:
- Currently enrolled in an HIV/AIDS clinical trial
- Currently psychotic based on standard assessment (e.g., MINI, Lecrubier et al., 1997)
- Any condition that, in the opinion of the investigator, would interfere with participation in the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: 1
|
Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
|
Placebo komparator: 2
Control
|
Health education and standard of care treatment
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Participation in screening for AIDS clinical trials to the point of determining eligibility, coded as yes/no.
Tidsramme: within the participant's 52 week follow up period
|
During interventions, participants in both arms receive contact information for local AIDS clinical trials units.
Two sources of data are used to determine whether screening occurred.
First, for participants screened at Beth Israel Medical Center, the study's main collaborating site, the screener notes the screening event in a participant status file.
Second, during follow-up interviews at 16 and 52 weeks post-baseline, participants' screening experiences at other units are assessed.
This self-reported screening is confirmed with the clinical trials units (all screening reports are verified).
|
within the participant's 52 week follow up period
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Enrollment into an AIDS clinical trial or HIV/AIDS biomedical research study
Tidsramme: within the participant's 52 week follow-up period
|
Two sources of data are used to determine whether enrollment occurred.
First, for participants screened at Beth Israel Medical Center, the study's main collaborating site, study staff confirms participation in the trial with participants and trials units and log this in a participant status file.
Second, during follow-up interviews at 16 and 52 weeks post-baseline, enrollment in studies and trials is assessed.
This self-reported enrollment is confirmed with the clinical trials units (all enrollment reports are verified).
|
within the participant's 52 week follow-up period
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Marya Gwadz, PhD, New York University
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ACT2
- R01AI070005 (U.S. NIH-stipend/kontrakt)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV-infeksjoner
-
Universidad del DesarrolloFullførtHealthcare Associated InfectionChile
-
Imelda Hospital, BonheidenFullførtHealthcare Associated InfectionBelgia
-
Centre Hospitalier Universitaire de NīmesRekrutteringEldre | Healthcare Associated InfectionFrankrike
-
Centre Hospitalier Universitaire, AmiensFullførtHealthcare Associated Infection | IglerFrankrike
-
Johns Hopkins UniversityFullførtHealthcare Associated Infection | Multiresistente organismer
-
University of PennsylvaniaFullførtAntimikrobiell resistensForente stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentFullførtMenneskelig mikrobiomForente stater
-
Universidad Autonoma de Nuevo LeonUkjentHelsetilknyttede infeksjoner
-
Children's Hospital Medical Center, CincinnatiAvsluttetAllogen hematopoetisk celletransplantasjonForente stater
-
University of Colorado, DenverUniversity of IowaFullførtHealth Care Associated Infection | HåndhygieneForente stater
Kliniske studier på Peer-driven intervention
-
Illinois Institute of TechnologyPatient-Centered Outcomes Research Institute; TrilogyFullførtPsykiske lidelserForente stater
-
University of California, Los AngelesFullført
-
Centers for Disease Control and PreventionFullførtHIV-infeksjoner | Hepatitt CForente stater
-
Duke UniversityNational Institute of Nursing Research (NINR)FullførtOvervekt | Hjerte-og karsykdommer | Kreft | Type II diabetes | Kollegastøtte og kronisk sykdomForente stater
-
University of California, San DiegoNational Cancer Institute (NCI); Dana-Farber Cancer Institute; University... og andre samarbeidspartnereRekruttering
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); The Emmes Company, LLC; National...FullførtOpioidoverdoseForente stater
-
University of PittsburghUniversity of Pittsburgh Medical CenterAvsluttetUngdomsadferd | Bruk av e-sigForente stater
-
Rhode Island HospitalBrown UniversityFullførtOpioidrelaterte lidelser | Opioidavhengighet | Opioidbruk | OpioidmisbrukForente stater
-
The N.1 Institute for Health (N.1)AccesetFullført
-
Medical College of WisconsinNational Institute on Drug Abuse (NIDA)FullførtSeksuelt overførbare sykdommer | HIVEl Salvador